Overview

Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia

Status:
Terminated

Trial end date:
2005-04-01

Target enrollment:

Participant gender:

Summary

The primary objective is to confirm the hypothesis that azithromycin (optimal dose once daily for three days) plus chloroquine is non-inferior to sulfadoxine-pyrimethamine plus chloroquine for the treatment of uncomplicated, symptomatic malaria due to P. falciparum.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Pfizer

Treatments:

Azithromycin
Chloroquine
Chloroquine diphosphate
Fanasil, pyrimethamine drug combination
Pyrimethamine
Sulfadoxine